• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA approves improved Oracle Micro catheter

Article

Endosonics has received Food and Drug Administration approvalfor its latest version of the Oracle Micro line of ultrasoundimaging catheters. The Pleasanton, CA, firm announced last monththat the FDA had given the go-ahead to Oracle Micro Plus,

Endosonics has received Food and Drug Administration approvalfor its latest version of the Oracle Micro line of ultrasoundimaging catheters. The Pleasanton, CA, firm announced last monththat the FDA had given the go-ahead to Oracle Micro Plus, whichcombines on a single catheter a solid-state imaging transducerand a percutaneous transluminal coronary angioplasty (PTCA) balloon.Endosonics said Oracle Micro Plus confers significant advantagesover its previous version of the product, which the FDA approvedlast year (SCAN 10/26/94). Oracle Micro Plus is especially wellsuited for coronary stenting procedures, the company said.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma

Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma

Jeff Hall
February 12th 2025
Article

Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 3

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 3

Jeff Hall
September 1st 2023
Podcast

In the third episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss the challenges of expanded breast cancer screening amid a backdrop of radiologist shortages and ever-increasing volume on radiology worklists.

Can Quantum Iterative Reconstruction Reinvent Photon-Counting CT Technology?

Can Quantum Iterative Reconstruction Reinvent Photon-Counting CT Technology?

Giuseppe Scappatura
February 11th 2025
Article

The advanced reconstruction algorithm offers optimal noise reduction, artifact correction, detailed spectral data and streamlined radiation dosing across cardiac, pulmonary and oncologic imaging.

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 2

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 2

Jeff Hall
August 23rd 2023
Podcast

In the second episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss recent studies published by the Journal of the American Medical Association (JAMA) that suggested moving to more of a risk-adapted model for mammography screening.

The Telling of Tales on Radiology Reports

The Telling of Tales on Radiology Reports

Eric Postal, MD
February 10th 2025
Article

Is there a certain amount of storytelling in diagnostic radiology?

Ultrasound Molecular Agent Gets FDA Fast Track Designation for Active Bowel Inflammation with Crohn’s Disease

Ultrasound Molecular Agent Gets FDA Fast Track Designation for Active Bowel Inflammation with Crohn’s Disease

Jeff Hall
February 7th 2025
Article

Phase 2 studies of the BR55 ultrasound contrast agent reportedly demonstrated a 95 percent accuracy in showing the expression of vascular endothelial growth factor receptor 2 (VEGFR2) in bowel segments reflecting active inflammation in patients with Crohn’s disease.

© 2025 MJH Life Sciences

All rights reserved.